0001209191-22-063059.txt : 20221230 0001209191-22-063059.hdr.sgml : 20221230 20221230211230 ACCESSION NUMBER: 0001209191-22-063059 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20221221 FILED AS OF DATE: 20221230 DATE AS OF CHANGE: 20221230 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Castelli Jeff CENTRAL INDEX KEY: 0001569225 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-33497 FILM NUMBER: 221503088 MAIL ADDRESS: STREET 1: 1 CEDAR BROOK DRIVE CITY: CRANBURY STATE: NJ ZIP: 08512 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: AMICUS THERAPEUTICS, INC. CENTRAL INDEX KEY: 0001178879 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 200422823 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 3675 MARKET STREET CITY: PHILADELPHIA STATE: PA ZIP: 19104 BUSINESS PHONE: (215) 921-7600 MAIL ADDRESS: STREET 1: 3675 MARKET STREET CITY: PHILADELPHIA STATE: PA ZIP: 19104 FORMER COMPANY: FORMER CONFORMED NAME: AMICUS THERAPEUTICS INC DATE OF NAME CHANGE: 20020729 3 1 doc3.xml FORM 3 SUBMISSION X0206 3 2022-12-21 0 0001178879 AMICUS THERAPEUTICS, INC. FOLD 0001569225 Castelli Jeff 3675 MARKET STREET PHILADELPHIA PA 19104 0 1 0 0 Chief Development Officer Common Stock 304255 D Stock Options (right to buy) 12.28 2025-06-01 Common Stock 50000 D Stock Options (right to buy) 9.03 2026-01-04 Common Stock 50000 D Stock Options (right to buy) 15.67 2028-01-03 Common Stock 39762 D Stock Options (right to buy) 10.04 2029-01-02 Common Stock 82644 D Stock Options (right to buy) 9.55 2030-01-02 Common Stock 107575 D Stock Options (right to buy) 21.78 2031-01-04 Common Stock 46396 D Stock Options (right to buy) 12.11 2032-01-03 Common Stock 108266 D Includes 161,910 Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of Amicus common stock. All of the options in this row are fully vested and exercisable as of December 21, 2022. The options reported in this row were granted on January 2, 2019 and become exercisable in a series of installments over a four year period with 25% vesting on the one year anniversary of the grant date and remaining 75% vesting ratably each month thereafter. As of December 21, 2022, 80,896 of such options were fully vested and exercisable and 1,748 remained unvested. The options reported in this row were granted on January 2, 2020 and become exercisable in a series of installments over a four year period with 25% vesting on the one year anniversary of the grant date and remaining 75% vesting ratably each month thereafter. As of December 21, 2022, 78,436 of such options were fully vested and exercisable and 29,139 remained unvested. The options reported in this row were granted on January 4, 2021 and become exercisable in a series of installments over a four year period with 25% vesting on the one year anniversary of the grant date and remaining 75% vesting ratably each month thereafter. As of December 21, 2022, 22,225 of such options were fully vested and exercisable and 24,171 remained unvested. The options reported in this row were granted on January 3, 2022 and will become exercisable in a series of installments over a four year period with 25% vesting on the one year anniversary of the grant date and remaining 75% vesting ratably each month thereafter. As of December 21, 2022, 0 of such options were fully vested and exercisable and 108,266 remained unvested. /s/ Christian Formica, Attorney-in-Fact 2022-12-30 EX-24 2 poa.txt POA DOCUMENT LIMITED POWER OF ATTORNEY FOR SECTION 16 REPORTING OBLIGATIONS The undersigned hereby constitutes and appoints each of Ellen Rosenberg, Daphne Quimi and Christian Formica, or any of them signing singly, and with full power of substitution, the undersigned's true and lawful attorney-in-fact to: 1. prepare and execute in the undersigned's name and on the undersigned's behalf, and submit to the U.S. Securities and Exchange Commission (the "SEC") a Form ID, including amendments thereto, and any other documents necessary or appropriate to obtain codes and passwords enabling the undersigned to make electronic filings with the SEC of reports required by Section16(a) of the Securities Exchange Act of 1934 or any rule or regulation of the SEC; 2. execute for and on behalf of the undersigned, in the undersigned's capacity as an officer and/or director of Amicus Therapeutics, Inc., a Delaware corporation (the "Company"), Forms 3, 4, and5 in accordance with Section 16(a) of the Securities Exchange Act of 1934 and the rules thereunder; 3. do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form 3, 4, or 5, complete and execute any amendment or amendments thereto, and file any such Form or amendment with the SEC and any stock exchange or similar authority, including filing this power of attorney with the SEC; and 4. take any other action necessary in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this power of attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion. The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934. This power of attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact. IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 20th day of December, 2022. /s/ Jeffrey P. Castelli Signature Jeffrey P. Castelli Print Name